Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 16/20 | 0.53 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2239862 | 0.89 | BTK (0.50) | BTKEGFRLCK | |
| SCHEMBL1921495 | 0.88 | BTK (0.53) | BTKMAPK11MAPK14EGFRLCK | |
| SCHEMBL9283600 | 0.88 | BTK (0.55) | BTKEGFRLCK | |
| SCHEMBL1921902 | 0.87 | BTK (0.46) | BTKEGFRLCK | |
| SCHEMBL1921672 | 0.87 | BTK (0.47) | BTKEGFRLCK | |
| SCHEMBL1921594 | 0.85 | BTK (0.56) | BTKMAPK11MAPK14EGFRLCK | |
| SCHEMBL1921675 | 0.85 | BTK (0.54) | BTKMAPK11MAPK14EGFRLCK | |
| SCHEMBL3246734 | 0.85 | BTK (0.45) | BTKEGFRLCK | |
| SCHEMBL1921718 | 0.85 | MAPK11 (0.52) | BTKMAPK11MAPK14EGFRLCK | |
| SCHEMBL1922320 | 0.85 | BTK (0.51) | BTKEGFRLCKHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140107150-A1 | New Compounds II | PROXIMAGEN LTD (GB) | 2014-04-17 | — | — | US | claimed |
| US-8633318-B2 | Compounds for treatment or prevention of inflammation, an inflammatory disease, or an immune or an autoimmune disorder | PROXIMAGEN LTD (GB) | 2014-01-21 | — | — | US | claimed |
| EP-2328895-B1 | Pyrazolo[4,3-c]pyridine compounds and their use as inhibitors of SSAO | PROXIMAGEN LTD (GB) | 2013-03-27 | — | — | EP | claimed |
| US-20110195992-A1 | NEW COMPOUNDS II | PROXIMAGEN LIMITED (GB) | 2011-08-11 | — | — | US | claimed |
| EP-3777846-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | BenevolentAI Cambridge Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | PROXIMAGEN, LLC | 2020-12-24 | — | — | US | disclosed |
| WO-2017098236-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | PROXIMAGEN LIMITED (GB) | 2017-06-15 | — | — | WO | disclosed |
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | UPSHER-SMITH LABORATORIES, INC. | 2016-04-28 | — | — | US | disclosed |
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | UPSHER-SMITH LABORATORIES, INC. | 2016-04-28 | — | — | US | disclosed |
| US-20160101072-A1 | Therapeutic uses of enzyme inhibitors | PROXIMAGEN LIMITED (GB) | 2016-04-14 | — | — | US | disclosed |
| US-20160101072-A1 | Therapeutic uses of enzyme inhibitors | PROXIMAGEN LIMITED (GB) | 2016-04-14 | — | — | US | disclosed |
| WO-2015189534-A1 | VAP-1 INHIBITORS FOR TREATING MUSCULAR DYSTROPHY | PROXIMAGEN LIMITED (GB) | 2015-12-17 | — | — | WO | disclosed |
| EP-2328895-B1 | Pyrazolo[4,3-c]pyridine compounds and their use as inhibitors of SSAO | PROXIMAGEN LTD (GB) | 2013-03-27 | — | — | EP | disclosed |
| EP-2328895-B1 | Pyrazolo[4,3-c]pyridine compounds and their use as inhibitors of SSAO | PROXIMAGEN LTD (GB) | 2013-03-27 | — | — | EP | disclosed |
| US-20110195992-A1 | NEW COMPOUNDS II | PROXIMAGEN LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| US-20110195992-A1 | NEW COMPOUNDS II | PROXIMAGEN LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| US-20110195992-A1 | NEW COMPOUNDS II | PROXIMAGEN LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| EP-2328895-A1 | NEW COMPOUNDS II | Proximagen Limited (GB) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010031791-A1 | NEW COMPOUNDS II | BIOVITRUM AB (PUBL) (SE) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010031791-A1 | NEW COMPOUNDS II | BIOVITRUM AB (PUBL) (SE) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | VAPB, VAPA, OPRL1 | BTK 4809/4885MAPK11 2718/4885MAPK14 3676/4885 |
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | VAPB, VAPA, AOX1 | BTK 4774/4885MAPK11 4307/4885MAPK14 4582/4885 |
| US-20110195992-A1 | NEW COMPOUNDS II | SSB, NFKBIA, ALOX15B | BTK 3544/4885MAPK11 2156/4885MAPK14 3464/4885 |
| US-20140107150-A1 | New Compounds II | SSB, NFKBIA, ALOX15B | BTK 3544/4885MAPK11 2156/4885MAPK14 3464/4885 |
| US-20160101072-A1 | Therapeutic uses of enzyme inhibitors | VAPB, VAPA, AOX1 | BTK 4739/4885MAPK11 4447/4885MAPK14 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.